Adeno-Associated Viral Vector-Mediated Expression of Endostatin Inhibits Tumor Growth and Metastasis in an Orthotopic Pancreatic Cancer Model in Hamsters

Takuji Noro,1,3 Koichi Miyake,1 Noriko Suzuki-Miyake,1 Tsutomu Igarashi,1 Eiji Uchida,2 Takeyuki Misawa,3 Yoji Yamazaki,3 and Takashi Shimada1

Departments of 1Biochemistry and Molecular Biology and 2Surgery for Organ Function and Biological Regulation, Nippon Medical School, Tokyo, Japan; and 3Department of Surgery, Jikei University School of Medicine, Tokyo, Japan

ABSTRACT

We examined the feasibility of using adeno-associated virus (AAV)-mediated systemic delivery of endostatin in gene therapy to treat metastasis of pancreatic cancer. We established an animal model of orthotopic metastatic pancreatic cancer in which the pancreatic cancer cell line PGHAM-1 was inoculated into the pancreas of Syrian golden hamsters. Transplanted cells proliferated rapidly and metastasized to the liver. An AAV vector expressing endostatin (5 × 1010 particles) was injected intra-muscularly into the left quadriceps or intraperitoneally into the portal vein. These routes of vector administration were evaluated by comparing various parameters of tumor development. Intramuscular injection of the vector modestly increased the serum endostatin level. The numbers of metastases and the incidence of hemorrhagic ascites were decreased in the treated animals. In contrast, the serum concentration of endostatin was significantly increased after intraportal injection of the vector. The antitumor effects on all parameters (including the size and microvessel density of primary pancreatic tumors, the sizes and number of liver metastases, and the incidence of hemorrhagic ascites) were significant. These results suggest that systemic delivery of endostatin represents a potentially effective treatment for pancreatic cancer and liver metastases. The route of vector administration influences the efficacy of AAV-mediated endostatin expression. Intraportal injection of the AAV vector appears to be more effective as an antiangiogenic gene therapy for pancreatic cancer.

INTRODUCTION

Pancreatic cancer is characterized by local invasion of adjacent structures and early metastasis to the liver and lymph nodes. Because of difficulties in early diagnosis and effective treatment, pancreatic cancer is often lethal (1). Local recurrence occurs in up to 85% of patients who undergo the currently available modality of surgical treatment (2). Despite extensive surgery, chemotherapy, and radiotherapy, the 5-year survival rate for patients with pancreatic cancer remains very low (3). Furthermore, the incidence of pancreatic cancer in the West has increased over the last four decades (4), indicating a pressing need for novel strategies that are effective against primary pancreatic cancer and the resultant liver metastases.

Gene therapy is an important option under active investigation for cancer therapy, although no definitive clinical efficacy has yet been demonstrated (5). Among a number of possible approaches, systemic gene therapy appears to be preferable for both inhibiting tumor growth and preventing metastases. The efficacy of systemic immunogene therapy using various cytokine genes has been demonstrated in various animal models (6–8). An alternative approach is the use of antiangiogenic genes. Because the neovascularization is essential for tumor growth and metastasis, the inhibition of angiogenesis is a promising anticancer strategy (9, 10).

The present study examines the feasibility of antiangiogenic gene therapy for treatment of pancreatic cancer using an orthotopic model. When PGHAM-1 derived from chemically induced hamster pancreatic cancer cells (11) is injected into the pancreas of hamsters, the cells develop ductal adenocarcinoma that closely resembles human pancreatic carcinoma and, like its human counterpart, frequently metastasizes to the liver. Thus, hamsters inoculated with PGHAM-1 cells represent an orthotopic pancreatic cancer model (12).

We used a classical adeno-associated virus (AAV) serotype 2 vector expressing endostatin to achieve a systemic state of antiangiogenesis in model animals. Endostatin is a 20-kDa COOH-terminal fragment of collagen and exerts powerful antiangiogenic activity through inhibition of endothelial cell proliferation and migration (13–15). The AAV vector is designed to be used for systemic delivery because it is replication defective, cannot cause insertional mutagenesis, and can be delivered to multiple tissues and organs at the same time. The AAV vector is an attractive gene therapy vector because it is replication-defective, not integrate into the host genome, is safe, and can be delivered to many tissues and organs at the same time.

MATERIALS AND METHODS

Plasmid Construction and Vector Production. The helper plasmid containing the complete AAV genome (pshb201) and the AAV serotype 2 packaging plasmid (pAAV/Ad) have been described previously (20). The stable mouse endostatin expression construct was used for the present study as described previously (21). Briefly, mouse endostatin cDNA was amplified by reverse transcription-polymerase chain reaction from total liver RNA using the oligonucleotide primers 5′-GCCGATCCCATATGCAAGGAGCTCTGACA-3′ and 5′-GGCTTGAGCAAGAAGCTCTGAGAACC-3′ and inserted into pHook1 (In vitro, Carlsbad, CA) to generate pHK-ES, in which the coding sequences for a murine immunoglobulin κ signal peptide and influenza virus hemagglutinin A epitope located upstream of the endostatin gene. The resulting plasmid was used for transfection of 293 cells to produce a recombinant AAV vector (rAAV-Endostatin).

In vitro Tube Formation Assay. To evaluate the antiangiogenic activity of AAV-End, in vitro tube formation assay was performed using an angiogenesis kit (Krabo, Okayama, Japan) as described previously (24). Briefly, human umbilical vein endothelial cells (HUVECs) cocultured with human fibroblasts were transduced with AAV-End or AAV-EGFP (1 × 1010 particles per mL) and cultured in medium containing vascular endothelial growth factor (VEGF). After 10 days, fixed cells were incubated with mouse antihuman CD31 (Kurabo, Okayama, Japan) and stained with metal-enhanced 3,3′-diaminobenzidine tetrahydrochloride. The total area and tube length were quantified using an angiogenesis image analyzer (Kurabo) and then statistically analyzed with Student’s t test.

Animal Experiments. Syrian golden hamsters were obtained from the Shizuoka Laboratory Animal Center (Shizuoka, Japan). All animal experiments were performed according to the guidelines established by the Ethical Committee of Nippon Medical School.

An orthotopic pancreatic cancer model was established according to the
AAV Vector-Mediated Expression of Endostatin in Syrian Golden Hamsters with Pancreatic Tumors. In the first experiment, we measured the concentrations of serum endostatin after intramuscular or intraportal injection of AAV-End (0.5 or 1.5 x 10^11 particles; Fig. 2A). The background level of serum endostatin in control hamsters that received intramuscular injection of PBS was 18.3 to 33.3 ng/mL. In accordance with previous reports (25, 26), AAV vector-

confirmed the AAV-mediated expression of biologically active endostatin. In the presence of VEGF, HUVECs generated tube-like structures (Fig. 1A). Transduction with a control AAV-EGFP vector did not affect tube formation (Fig. 1B). However, the number of tubes in cells transduced with AAV-End was significantly reduced (Fig. 1C). Measurements of tube area (Fig. 1D) and length (Fig. 1E) confirmed that AAV-End was able to inhibit in vitro angiogenesis.

**Generation of a Hamster Pancreatic Cancer Model.** We generated an orthotopic model of pancreatic cancer by direct inoculation of PGHAM-1 cells into the splenic lobe of the pancreas. The inoculated cells proliferated rapidly and formed a mass in all animals approximately 7 days after transplantation. Metastases to the liver were observed in all animals after 3 weeks. Most of the hamsters bearing transplanted tumors developed massive hemorrhagic ascites. All of the transplant-treated animals died around 4 weeks after transplantation due to advanced tumor growth and metastases.

**RESULTS**

AAV Vector-Mediated Expression of Endostatin In vitro. We generated an AAV vector containing the secretable form of the murine endostatin gene driven by the CAG promoter (AAV-End). Assays of in vitro tube formation using HUVECs cocultured with fibroblasts confirmed the AAV-mediated expression of biologically active endostatin. In the presence of VEGF, HUVECs generated tube-like structures (Fig. 1A). Transduction with a control AAV-EGFP vector did not affect tube formation (Fig. 1B). However, the number of tubes in cells transduced with AAV-End was significantly reduced (Fig. 1C). Measurements of tube area (Fig. 1D) and length (Fig. 1E) confirmed that AAV-End was able to inhibit in vitro angiogenesis.

**FIG. 1. Antiangiogenic activity of AAV-End in tube formation assay.** HUVECs cocultured with human fibroblasts in the presence of VEGF were incubated with PBS (A), AAV-EGFP (B), or AAV-End (C). The area (D) and length (E) of tube-like structures were measured quantitatively using an image analyzer. *, P < 0.05; **, P < 0.01.
mediated gene expression increased gradually, with a peak at 4 to 6 weeks after either intramuscular or intraportal injection. Intramuscular injection moderately increased the serum endostatin level, whereas significantly higher levels of serum endostatin were observed after intraportal injection. A 3-fold increase of the vector dose only slightly raised the serum endostatin level (Fig. 2A).

The growth rate of PGHAM-1 cells is very rapid (11, 27). Therefore, to study the antitumor activity of the AAV vector, we injected the AAV vector (0.5 × 10^{11} particles) 21 days before inoculation with tumor cells. All animals were sacrificed 21 days after transplantation with tumor cells (42 days after vector injection) to allow biochemical and histologic analyses. The concentrations of serum endostatin at autopsy are shown Fig. 2B. The background level of serum endostatin (50.8–51.9 ng/mL) was not changed by either laparotomy or intraportal injection of PBS or AAV-EGFP. Intramuscular injection of AAV-End moderately increased the serum endostatin level (124.5 ± 27.0 ng/mL), whereas the level of endostatin expression became significantly higher after intraportal injection (225.5 ± 31.0 ng/mL; Fig. 2B).

Distribution of AAV-End was determined by PCR analysis of the EGFP sequence, which was derived from the second gene in the AAV-End vector. When AAV-End was injected into the left quadriceps muscle, the EGFP-specific 277-bp fragment was detected only at the injected site. On the other hand, the EGFP sequence was detected not only in the liver but also in the kidneys, heart, and pancreas after intraportal injection (Fig. 3A and B).

**Effects on the Growth of the Primary Pancreatic Tumor.** We evaluated the growth rate of the primary tumor in the pancreas (Fig. 4A and B). The average size of the tumor was 395.0 ± 38.8 mm^3. The growth rate was not significantly restricted by intramuscular injection of AAV-End (311.9 ± 66.5 mm^3). In contrast, intraportal administration of AAV-End significantly decreased tumor volume to 174.0 ± 28.0 mm^3.

Tumor sections were stained with an antibody against von Willebrand factor, and the vasculature was subsequently evaluated (Fig. 4C and D). Microvessel density in the tumor was significantly decreased by AAV-End, irrespective of the injection route. The average vascular density in hamsters that received intramuscular injection with AAV-End was 15.6 ± 2.3 compared with 39.0 ± 6.0 in the control hamsters that received intramuscular injection with AAV-EGFP. The average vascular density in hamsters that received intraportal injection with AAV-End was 6.7 ± 0.9 compared with 36.5 ± 3.5 in the controls that received intraportal injection with AAV-EGFP.

**Effects on Liver Metastasis and Massive Hemorrhagic Ascites.** We examined the number and size of the liver metastases (Fig. 5A–C). Compared with AAV-EGFP, intramuscular injection of AAV-End decreased the number (3.5 versus 1.7; P < 0.05) but not the size of metastases in the liver, based on maximal diameter (2.2 versus 2.8 mm). In contrast, intraportal injection of AAV-End significantly reduced both the number (4.7 versus 1.0; P < 0.01) and size (3.7 versus 0.8 mm; P < 0.05) of the metastases.

Massive hemorrhagic ascites are thought to be a parameter of tumor invasion and peritoneal dissemination. Bloody ascites developed in 75.0% (six of eight) of hamsters that received intramuscular injection with AAV-EGFP. Laparotomy followed by intraportal injection with AAV-EGFP slightly increased the incidence rate to 87.5% (seven of eight). The formation of ascites was significantly inhibited after AAV-End injection by either route. The incidence of ascite formation in hamsters that received AAV via intramuscular injection and via intraportal injection was 15.4% (2 of 13) and 18.2% (2 of 11), respectively.
DISCUSSION

In the present study, we compared the intramuscular and intraportal routes of AAV vector administration in terms of the relative potency of antiangiogenic gene therapy for pancreatic cancer and liver metastasis using an orthotopic animal model. AAV vectors have often been injected intramuscularly to systemically deliver various types of secretable protein molecules because of the easy accessibility and decreased invasiveness of this route (22, 28–30). Another advantage of muscle-directed gene therapy is minimal spill-over of the injected vectors (22). Our experimental system confirmed that the vector sequence is localized at the injection site. Compared with the intramuscular route, intraportal injection is more invasive and is likely to be more hazardous for liver function. Despite these potential disadvantages, liver-directed gene transfer has been postulated to achieve more efficient transgene expression (28, 29, 31). In our experiments with immunocompetent hamsters, we indeed confirmed the reported finding that expression mediated by AAV is more efficient in the liver than in muscle.

The antitumor effects of endostatin appear to be closely correlated with its serum concentration. Low levels of serum endostatin after AAV-IM injection certainly reduced the number of metastases and the incidence of hemorrhagic ascites. However, primary tumor growth was not evidently inhibited. In contrast, intraportal injection of AAV resulted in high levels of serum endostatin followed by significant inhibition of both primary tumor growth and the development of metastasis. Another factor that needs to be considered here is that the concentration of endostatin may be much higher in the liver, where the gene is expressed, than in serum. Liver-directed gene transfer of the angiostatic gene is a valuable treatment option for primary liver tumors and liver metastases.

The important point of this work is that we used an orthotopic animal model of metastatic pancreatic cancer. Heterotopic graft models used in previous studies ignore the histologic and anatomic specificity of the organs of the primary as well as the distant sites (32). Consequently, these studies do not adequately serve as preclinical trials for human gene therapy. Orthotopic grafts are essential to evaluation of the routes of gene transfer, especially the assessment of metastasis. The disadvantage of this model is that PGHAM-1 cells grow and invade very quickly. Under the experimental conditions in this investigation, all transplant-treated hamsters died at about 4 weeks after cell inoculation, irrespective of treatment. The statistically significant inhibition of primary tumor growth and metastasis did not immediately impact the survival rate of the treated animals. The overall effects of antiangiogenic cancer therapy must therefore be further studied using a different model system in which transplanted cancer cells grow more slowly, ideally in a manner consistent with naturally occurring human cancer cells.

To achieve the antiangiogenic state in model animals, we used classical AAV serotype 2 vectors in this experiment. The advantages of AAV vectors include a lack of pathogenicity, low immunogenicity, stable expression from either the integrated or episomal genome, and the ability to transduce growth-arrested cells (17, 33, 34). One problem is that it takes several weeks to reach the maximal level of transgene expression. Therefore, to evaluate the efficacy of cancer gene therapy in a transplant-treated model animal, the AAV vector must be injected before tumor inoculation (35–37). The disadvantages of AAV serotype 2 vectors include a relatively low transduction efficiency and the difficulty of large-scale production. Recently, many different serotypes of AAV have been characterized (38), and AAV serotype 1 vectors have been shown to be highly efficient in gene transfer into both muscle and liver in animal models (39). AAV serotype 1 vectors may turn out to be the vector of choice for orthotopic animal models.
Fig. 5. Effects of AAV-mediated endostatin expression on liver metastases. Numbers (B) and sizes (C) of metastatic tumors in the liver (A) were measured. Arrows indicate the location of liver metastases (n = 4). *, P < 0.05; **, P < 0.01; ***, P > 0.05; ****, P < 0.05. IM, intramuscular injection; IPO, intraportal injection.

choice for additional preclinical and clinical studies of systemic antiangiogenic cancer gene therapy.

ACKNOWLEDGMENTS

We thank Manami Okabe and Motoko Yamamoto for excellent technical assistance. In addition, we thank Takayuki Aimoto, Munehsu Fujihara, and Makoto Hiroi for advice and expertise.

REFERENCES

Adeno-Associated Viral Vector-Mediated Expression of Endostatin Inhibits Tumor Growth and Metastasis in an Orthotropic Pancreatic Cancer Model in Hamsters

Takuji Noro, Koichi Miyake, Noriko Suzuki-Miyake, et al.

Cancer Res 2004;64:7486-7490.

Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/64/20/7486

Cited articles
This article cites 38 articles, 18 of which you can access for free at:
http://cancerres.aacrjournals.org/content/64/20/7486.full#ref-list-1

Citing articles
This article has been cited by 3 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/64/20/7486.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://cancerres.aacrjournals.org/content/64/20/7486.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.